All News
Filter News
Found 760 articles
-
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/3/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
-
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting
11/3/2023
HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data from the Company's Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting
11/2/2023
HotSpot Therapeutics, Inc. announced it will present preclinical data from the Company's highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 program in an oral presentation at the 2023 American Society of Hemotology Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.
-
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
11/1/2023
Sensei Biotherapeutics, Inc. today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
-
First Mice Engineered to Survive COVID-19 Like Young, Healthy Humans
11/1/2023
Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.
-
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
10/24/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP).
-
After the FDA released draft guidance on increasing diversity in clinical trials, companies have been left to figure out the details. Here’s what experts say is working.
-
Saphetor Partners with ICON to Develop Innovative Data-centric Approach to Precision Medicine Clinical Trial Strategies to Help Support Unique Patients
10/17/2023
Saphetor SA announce that it is partnering with world-leading healthcare intelligence and clinical research organisation ICON to develop an innovative approach to support the planning and execution of clinical trials in the precision medicine and rare diseases space.
-
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
10/17/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023.
-
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
10/11/2023
Elicio Therapeutics, Inc. announced that it will present updated preliminary data from the ongoing Phase 1 study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008.
-
GENZEVA and RYLTI Partner to Develop a Groundbreaking Application to More Clearly Understand the Molecular Mechanisms of Disease
10/6/2023
Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, has partnered with tech innovator RYLTI to develop an innovative groundbreaking application of AI Knowledge Engineering and use of a biomimetic digital twin ecosystem for advanced genomic research.
-
HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting
9/27/2023
HotSpot Therapeutics, Inc. today announced it will present additional preclinical data from the Company's CBL-B program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, CA.
-
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
9/7/2023
Elicio Therapeutics, Inc. today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008.
-
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
8/8/2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2023, and provided an update on corporate progress.
-
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
6/28/2023
AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.
-
CureDuchenne Ventures Invests in MyoGene Bio and its AAV-Delivered CRISPR/Cas9 Gene Editing Approach
5/11/2023
CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy.
-
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
5/8/2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate progress.
-
Bayer Opens First Co.Lab Life Science Incubator in Cambridge
5/4/2023
Bayer AG announced the inauguration of its new life science incubator dubbed “Co.Lab Cambridge” located in Kendall Square in Cambridge, U.S. Bayer’s Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies entrepreneurs with access to Bayer’s enterprise wide expertise in addition to state-of-the-art laboratory and office space.
-
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023
4/19/2023
HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data on the Company's casitas B-lineage lymphoma-B (CBL-B) program in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting
4/17/2023
Flare Therapeutics today highlighted the first preclinical data from its lead compound FX-909, a novel, small molecule peroxisome proliferator-activated receptor gamma (PPARG) inhibitor to potentially treat patients with advanced urothelial cancer (UC), in an oral presentation and poster format at the AACR Annual Meeting being held in Orlando, FL from April 14-19, 2023.